Microbiota transplantation reveals beneficial impact of berberine on hepatotoxicity by improving gut homeostasis

Science China Life Sciences

Volumn 61, Issue 12, 2018, Pages 1537-1544

  Qin, Chenjie ^a,b   Zhang, Huilu ^c   Zhao, Linghao ^a,b   Zeng, Min ^a,b   Huang, Weijian ^a,b   Fu, Gongbo ^a,b   Zhou, Weiping ^a,b   Wang, Hongyang ^a,b   Yan, Hexin ^a,b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b National Center for Liver Cancer   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

berberine; fecal microbiota transplantation; gut homeostasis; hepatotoxicity

Indexed keywords

BERBERINE;

ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; DYSBIOSIS; FECAL MICROBIOTA TRANSPLANTATION; HOMEOSTASIS; INTESTINE; INTESTINE FLORA; MALE; MICROBIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TOXIC HEPATITIS;

ANIMALS; BERBERINE; CHEMICAL AND DRUG INDUCED LIVER INJURY; DISEASE MODELS, ANIMAL; DYSBIOSIS; FECAL MICROBIOTA TRANSPLANTATION; GASTROINTESTINAL MICROBIOME; HOMEOSTASIS; INTESTINES; MALE; MICE, INBRED C57BL; RATS, SPRAGUE-DAWLEY;

EID: 85038640540     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-017-9202-0     Document Type: Article

References (55)

1. Alolga, R.N., Fan, Y., Chen, Z., Liu, L.W., Zhao, Y.J., Li, J., Chen, Y., Lai, M.D., Li, P., and Qi, L.W. (2016). Significant pharmacokinetic differences of berberine are attributable to variations in gut microbiota between Africans and Chinese. Sci Rep 6, 27671.
2. Alpini, G., Lenzi, R., Sarkozi, L., and Tavoloni, N. (1988). Biliary physiology in rats with bile ductular cell hyperplasia. Evidence for a secretory function of proliferated bile ductules. J Clin Investig 81, 569–578.
3. Bakken, J.S., Borody, T., Brandt, L.J., Brill, J.V., Demarco, D.C., Franzos, M.A., Kelly, C., Khoruts, A., Louie, T., Martinelli, L.P., Moore, T.A., Russell, G., Surawicz, C., and Surawicz, C. (2011). Treating clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 9, 1044–1049.
4. Bernal, W., and Wendon, J. (2013). Acute liver failure. N Engl J Med 369, 2525–2534.
5. Betrapally, N.S., Gillevet, P.M., and Bajaj, J.S. (2016). Gut microbiome and liver disease. Transl Res 179, 49–59.
6. Bojanova, D.P., and Bordenstein, S.R. (2016). Fecal transplants: what is being transferred? PLoS Biol 14, e1002503.
7. Borody, T.J., and Khoruts, A. (2011). Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol 9, 88–96.
8. Cao, Y., Pan, Q., Cai, W., Shen, F., Chen, G.Y., Xu, L.M., and Fan, J.G. (2016). Modulation of gut microbiota by berberine improves steatohepatitis in high-fat diet-fed BALB/C mice. Arch Iranian Med 19, 197–203.
9. Caradonna, L., Amati, L., Magrone, T., Pellegrino, N.M., Jirillo, E., and Caccavo, D. (2000). Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance. J Endotoxin Res 6, 205–214.
10. Chen, C., Yu, Z., Li, Y., Fichna, J., and Storr, M. (2014). Effects of berberine in the gastrointestinal tract—A review of actions and therapeutic implications. Am J Chin Med 42, 1053–1070.
11. Chen, X., Zhang, Y., Zhu, Z., Liu, H., Guo, H., Xiong, C., Xie, K., Zhang, X., and Su, S. (2016). Protective effect of berberine on doxorubicin-induced acute hepatorenal toxicity in rats. Mol Med Rep 13, 3953–3960.
12. Cicero, A.F., and Baggioni, A. (2016). Berberine and its role in chronic disease. Adv Exp Med Biol 928, 27–45.
13. Davern, T.J. (2012). Drug-induced liver disease. Clin Liver Dis 16, 231–245.
14. De Minicis, S., Rychlicki, C., Agostinelli, L., Saccomanno, S., Candelaresi, C., Trozzi, L., Mingarelli, E., Facinelli, B., Magi, G., Palmieri, C., Marzioni, M., Benedetti, A., and Svegliati-Baroni, G. (2014). Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology 59, 1738–1749.
15. Derosa, G., Maffioli, P., and Cicero, A.F.G. (2012). Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther 12, 1113–1124.
16. Dong, H., Zhao, Y., Zhao, L., and Lu, F. (2013). The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials. Planta Med 79, 437–446.
17. Francis, H., Franchitto, A., Ueno, Y., Glaser, S., DeMorrow, S., Venter, J., Gaudio, E., Alvaro, D., Fava, G., Marzioni, M., Vaculin, B., and Alpini, G. (2007). H3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/ERK1/2/ELK-1 pathway. Lab Invest 87, 473–487.
18. Frazier, T.H., DiBaise, J.K., and McClain, C.J. (2011). Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury. JPEN J Parenter Enteral Nutr 35, 14S–20S.
19. Fukui, H. (2015). Gut microbiota and host reaction in liver diseases. Microorganisms 3, 759–791.
20. Gaudio, E., Taddei, G., Vetuschi, A., Sferra, R., Frieri, G., Ricciardi, G., and Caprilli, R. (1999). Dextran sulfate sodium (DSS) colitis in rats: clinical, structural, and ultrastructural aspects. Dig Dis Sci 44, 1458–1475.
21. Gregory, J.C., Buffa, J.A., Org, E., Wang, Z., Levison, B.S., Zhu, W., Wagner, M.A., Bennett, B.J., Li, L., DiDonato, J.A., Lusis, A.J., and Hazen, S.L. (2015). Transmission of atherosclerosis susceptibility with gut microbial transplantation. J Biol Chem 290, 5647–5660.
22. Gu, Y., Zhang, Y., Shi, X., Li, X., Hong, J., Chen, J., Gu, W., Lu, X., Xu, G., and Ning, G. (2010). Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics. Talanta 81, 766–772.
23. Gupta, S., Allen-Vercoe, E., and Petrof, E.O. (2016). Fecal microbiota transplantation: in perspective. Therapeutic Adv Gastroenterol 9, 229–239.
24. Habtemariam, S. (2016). Berberine and inflammatory bowel disease: a concise review. Pharmacol Res 113, 592–599.
25. Han, J., Lin, H., and Huang, W. (2011). Modulating gut microbiota as an antidiabetic mechanism of berberine. Med Sci Monit 17, RA164–RA167.
26. He, Q., Mei, D., Sha, S., Fan, S., Wang, L., and Dong, M. (2016). ERKdependent mTOR pathway is involved in berberine-induced autophagy in hepatic steatosis. J Mol Endocrinol 59, X1–X1.
27. Hwang, J.M., Wang, C.J., Chou, F.P., Tseng, T.H., Hsieh, Y.S., Lin, W.L., and Chu, C.Y. (2002). Inhibitory effect of berberine on tert-butyl hydroperoxide- induced oxidative damage in rat liver. Arch Toxicol 76, 664–670.
28. Imenshahidi, M., and Hosseinzadeh, H. (2016). Berberis Vulgaris and Berberine: an update review. Phytother Res 30, 1745–1764.
29. Jayashree, B., Bibin, Y.S., Prabhu, D., Shanthirani, C.S., Gokulakrishnan, K., Lakshmi, B.S., Mohan, V., and Balasubramanyam, M. (2014). Increased circulatory levels of lipopolysaccharide (LPS) and zonulin signify novel biomarkers of proinflammation in patients with type 2 diabetes. Mol Cell Biochem 388, 203–210.
30. Ji, H.F., and Shen, L. (2011). Berberine: a potential multipotent natural product to combat Alzheimer’s disease. Molecules 16, 6732–6740.
31. Khin Maung, U., Myo, K., Nyunt Nyunt, W., Aye, K., and Tin, U. (1985). Clinical trial of berberine in acute watery diarrhoea. Br Med J 291, 1601–1605.
32. Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., Wang, S., Wu, J., Wang, Y., Li, Z., Liu, J., and Jiang, J.D. (2004). Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10, 1344–1351.
33. Mekawi, M. (1966). Effect of berberine alkaloid on cholera Vibro and its endotoxin. J Egypt Med Assoc 49, 554–559.
34. Mo, C., Wang, L., Zhang, J., Numazawa, S., Tang, H., Tang, X., Han, X., Li, J., Yang, M., Wang, Z., Wei, D., and Xiao, H. (2014). The crosstalk between Nrf2 and AMPK signal pathways is important for the anti-inflammatory effect of berberine in LPS-stimulated macrophages and endotoxin- shocked mice. Antioxid Redox Signal 20, 574–588.
35. Pang, B., Zhao, L.H., Zhou, Q., Zhao, T.Y., Wang, H., Gu, C.J., and Tong, X.L. (2015). Application of berberine on treating type 2 diabetes mellitus. Int J Endocrinol 2015, 1–12.
36. Potdar, D., Hirwani, R.R., and Dhulap, S. (2012). Phyto-chemical and pharmacological applications of Berberis aristata. Fitoterapia 83, 817–830.
37. Qin, N., Yang, F., Li, A., Prifti, E., Chen, Y., Shao, L., Guo, J., Le Chatelier, E., Yao, J., Wu, L., Zhou, J., Ni, S., Liu, L., Pons, N., Batto, J.M., Kennedy, S.P., Leonard, P., Yuan, C., Ding, W., Chen, Y., Hu, X., Zheng, B., Qian, G., Xu, W., Ehrlich, S.D., Zheng, S., and Li, L. (2014). Alterations of the human gut microbiome in liver cirrhosis. Nature 513, 59–64.
38. Quigley, E.M., Stanton, C., and Murphy, E.F. (2013). The gut microbiota and the liver. Pathophysiological and clinical implications. J Hepatol 58, 1020–1027.
39. Rabbani, G.H., Butler, T., Knight, J., Sanyal, S.C., and Alam, K. (1987). Randomized controlled trial of berberine sulfate therapy for diarrhea due to enterotoxigenic Escherichia coli and Vibrio cholerae. J Infect Dis 155, 979–984.
40. Savage, D.C., and Dubos, R. (1968). Alterations in the mouse cecum and its flora produced by antibacterial drugs. J Exp Med 128, 97–110.
41. Singh, A., Bajpai, V., Srivastava, M., Arya, K.R., and Kumar, B. (2014). Rapid profiling and structural characterization of bioactive compounds and their distribution in different parts of Berberis petiolaris Wall. ex G. Don applying hyphenated mass spectrometric techniques. Rapid Commun Mass Spectrom 28, 2089–2100.
42. Sun, D., Abraham, S.N., and Beachey, E.H. (1988). Influence of berberine sulfate on synthesis and expression of Pap fimbrial adhesin in uropathogenic Escherichia coli. Antimicrob Agents Chemother 32, 1274–1277.
43. Tang, L.Q., Ni, W.J., Cai, M., Ding, H.H., Liu, S., and Zhang, S.T. (2016). Renoprotective effects of berberine and its potential effect on the expreßsion of β-arrestins and intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in streptozocin-diabetic nephropathy rats. J Diabetes 8, 693–700.
44. Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., Magrini, V., Mardis, E.R., and Gordon, J.I. (2006). An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027–131.
45. Turnbaugh, P.J., Ridaura, V.K., Faith, J.J., Rey, F.E., Knight, R., and Gordon, J.I. (2009). The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 1, 6ra14–6ra14.
46. Wyatt, J., Vogelsang, H., Hübl, W., Waldhoer, T., and Lochs, H. (1993). Intestinal permeability and the prediction of relapse in Crohri’s disease. Lancet 341, 1437–1439.
47. Yao, J., Kong, W.J., and Jiang, J.D. (2015). Learning from berberine: treating chronic diseases through multiple targets. Sci China Life Sci 58, 854–859.
48. Yu, L.X., Yan, H.X., Liu, Q., Yang, W., Wu, H.P., Dong, W., Tang, L., Lin, Y., He, Y.Q., Zou, S.S., Wang, C., Zhang, H.L., Cao, G.W., Wu, M.C., and Wang, H.Y. (2010). Endotoxin accumulation prevents carcinogen- induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 52, 1322–1333.
49. Zhang, H.L., Yu, L.X., Yang, W., Tang, L., Lin, Y., Wu, H., Zhai, B., Tan, Y.X., Shan, L., Liu, Q., Chen, H.Y., Dai, R.Y., Qiu, B.J., He, Y.Q., Wang, C., Zheng, L.Y., Li, Y.Q., Wu, F.Q., Li, Z., Yan, H.X., and Wang, H.Y. (2012a). Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. J Hepatol 57, 803–812.
50. Zhang, P., Ma, D., Wang, Y., Zhang, M., Qiang, X., Liao, M., Liu, X., Wu, H., and Zhang, Y. (2014a). Berberine protects liver from ethanol-induced oxidative stress and steatosis in mice. Food Chem Toxicol 74, 225–232.
51. Zhang, X., Zhao, Y., Zhang, M., Pang, X., Xu, J., Kang, C., Li, M., Zhang, C., Zhang, Z., Zhang, Y., Li, X., Ning, G., and Zhao, L. (2012b). Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS ONE 7, e42529.
52. Zhang, Z., Zhang, H., Li, B., Meng, X., Wang, J., Zhang, Y., Yao, S., Ma, Q., Jin, L., Yang, J., Wang, W., and Ning, G. (2014b). Berberine activates thermogenesis in white and brown adipose tissue. Nat Commun 5, 5493.
53. Zhao, G., Yu, L., Gao, W., Duan, W., Jiang, B., Liu, X., Zhang, B., Liu, Z., Zhai, M., Jin, Z., Yu, S., and Wang, Y. (2016). Berberine protects rat heart from ischemia/reperfusion injury via activating JAK2/STAT3 signaling and attenuating endoplasmic reticulum stress. Acta Pharmacol Sin 37, 354–367.
54. Zhou, J.Y., Zhou, S.W., Zhang, K.B., Tang, J.L., Guang, L.X., Ying, Y., Xu, Y., Zhang, L., and Li, D.D. (2008). Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats. Biol Pharmaceut Bull 31, 1169–1176.
55. Zhu, W., Gregory, J.C., Org, E., Buffa, J.A., Gupta, N., Wang, Z., Li, L., Fu, X., Wu, Y., Mehrabian, M., Sartor, R.B., McIntyre, T.M., Silverstein, R.L., Tang, W.H.W., DiDonato, J.A., Brown, J.M., Lusis, A.J., and Hazen, S.L. (2016). Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell 165, 111–124.